ghk-cu upregulates col3a1 Copper Peptide Regeneration Review (2018) — Research Summary GHK-CU

This regulatory status means that quality control varies significantly between suppliers, reinforcing the importance of sourcing through a licensed medical provider rather than unregulated online sources

A small, 7-day clinical trial, published in 2002 offered very little information other than the reporting of no significant adverse effects. Results from a clinical safety and pharmacokinetics study on BPC-157 registered with clinicaltrials.gov in 2015 have not yet been released (study status reported as unknown)

Ist BPC-157 im Magen stabil

intramuscular route: count injections given Visit 4 (week 52) Anamnesis: record lifestyle habits and use of alcohol Symptoms: record paresthesia, asthenia, loss or reduction of appetite, sadness or change in level of happiness, and concomitant pharmacological treatment Physical examination: for Hunters glositis, positional and vibrational sensitivity Record concomitant treatment Questionnaires: EuroQoL-5D, satisfaction and preferences Assessment of haemogram and serum vitamin B12 concentration Assessment of adverse effects Assess adherence to treatment: oral route count number of vials used